Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 37

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 37
---
 of peer companies performed by Compensia to inform the Compensation Committee’s decisions about overall compensation opportunities and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing targeted compensation levels. The Compensation Committee does not benchmark specific compensation elements or total compensation to any specific percentile relative to the peer companies or the broader United States market. Instead, the Compensation Committee applies judgment and discretion in establishing targeted pay levels, taking into account not only competitive market data, but also factors such as Company, business and individual performance, scope of responsibility, critical needs and skill sets, leadership potential and succession planning.

The members of the Compensation Committee are Carrie S. Cox, Nishan de Silva, M.D., MBA, Kemal Malik, M.B.B.S., and Patrick Zenner, M.B.A. Carrie S. Cox serves as Chairman of the Compensation Committee. Our Board has determined that

<div align='center'>21</div>

each of Ms. Cox, Dr. Malik, and Mr. Zenner and our former director and Compensation Committee member Aymeric Sallin, is independent under the applicable SEC and Nasdaq rules, including the heightened standard for independence specific to members of a compensation committee, and is a “non‑employee director” as defined in Rule 16b‑3 promulgated under the Exchange Act.

In 2024, the Compensation Committee met seven times.

#### Nominating and Corporate Governance Committee
Our Nominating and Corporate Governance Committee’s responsibilities include:

• identifying individuals qualified to become board members;

• recommending to our Board the persons to be nominated for election as directors and to each board committee;

• reviewing and making recommendations to our Board with respect to management succession planning;

• developing and recommending to our Board corporate governance principles; and

• overseeing a periodic assessment of our Board.

The Nominating and Corporate Governance Committee charter is available on the “Corporate Governance” section of the “Investors” page of our website at www.cartesiantherapeutics.com. The members of the Nominating and Corporate Governance Committee are Timothy C. Barabe, M.B.A., Murat Kalayoglu, M.D., Ph.D., Michael Singer, M.D., Ph.D., and Patrick Zenner, M.B.A. Mr. Zenner serves as the Chairman of the Nominating and Corporate Governance Committee. Our Board has determined that each of Mr. Barabe, Dr. Kalayoglu, Dr. Singer, and Mr. Zenner is independent under the applicable Nasdaq rules.

In